Basit öğe kaydını göster

Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial

dc.contributor.authorGhia, Paolo
dc.contributor.authorFurman, Richard R.
dc.contributor.authorChanan-Khan, Asher
dc.contributor.authorKater, Arnon P.
dc.contributor.authorByrd, John C.
dc.contributor.authorHamdy, Ahmed
dc.contributor.authorPatel, Priti
dc.contributor.authorHiggins, Kara
dc.contributor.authorSohoni, Sophia
dc.contributor.authorJurczak, Wojciech
dc.contributor.authorHillmen, Peter
dc.contributor.authorIzumi, Raquel
dc.contributor.authorRothbaum, Wayne
dc.contributor.authorRobak, Tadeusz
dc.contributor.authorStilgenbauer, Stephan
dc.contributor.authorLepretre, Stephane
dc.contributor.authorSeymour, John F.
dc.contributor.authorPinilla-Ibarz, Javier
dc.contributor.authorMato, Anthony
dc.contributor.authorGarcia-Marco, Jose A.
dc.contributor.authorKay, Neil
dc.contributor.authorIlles, Arpad
dc.contributor.authorYENEREL, Mustafa Nuri
dc.contributor.authorO'Brien, Susan
dc.date.accessioned2022-07-04T16:29:04Z
dc.date.available2022-07-04T16:29:04Z
dc.date.issued2021
dc.identifier.citationByrd J. C. , Hillmen P., Ghia P., Kater A. P. , Chanan-Khan A., Furman R. R. , O'Brien S., YENEREL M. N. , Illes A., Kay N., et al., "Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial", JOURNAL OF CLINICAL ONCOLOGY, cilt.39, sa.31, ss.3441-3454, 2021
dc.identifier.issn0732-183X
dc.identifier.othervv_1032021
dc.identifier.otherav_e79ddb13-a9ea-4e3f-9b20-172cfefe1074
dc.identifier.urihttp://hdl.handle.net/20.500.12627/185162
dc.identifier.urihttps://doi.org/10.1200/jco.21.01210
dc.description.abstractPURPOSE Among Bruton's tyrosine kinase inhibitors, acalabrutinib has greater selectivity than ibrutinib, which we hypothesized would improve continuous therapy tolerability. We conducted an open-label, randomized, noninferiority, phase III trial comparing acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia (CLL).
dc.language.isoeng
dc.subjectHealth Sciences
dc.subjectOncology
dc.subjectOnkoloji
dc.subjectİç Hastalıkları
dc.subjectDahili Tıp Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectONKOLOJİ
dc.titleAcalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
dc.typeMakale
dc.relation.journalJOURNAL OF CLINICAL ONCOLOGY
dc.contributor.departmentOhio State University , ,
dc.identifier.volume39
dc.identifier.issue31
dc.identifier.startpage3441
dc.identifier.endpage3454
dc.contributor.firstauthorID3398815


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster